Vale Luke, Steffens Harvey, Donaldson Cam
Health Economics Research Unit, University of Aberdeen, Aberdeen AB25 2ZD, Scotland.
Pharmacoeconomics. 2004;22(14):943-54. doi: 10.2165/00019053-200422140-00004.
There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the community compared with that administered in hospital.
This paper aimed to model the cost and benefits of community compared with hospital thrombolysis from the UK NHS perspective, using efficacy data from the GREAT.
A decision-analytic approach was used to model these two alternatives. Resource use and cost estimates were estimated for a single tertiary centre. Estimates of effectiveness in life-years were obtained from the 4-year follow-up for patients recruited to the GREAT, using declining exponential approximation of life expectancy. Costs are in pounds sterling, 2000/1 values.
Community thrombolysis had an average life expectancy of 12.48 years and hospital thrombolysis had an average life expectancy of 12.39 years. Costs were 361 pounds sterling for community thrombolysis and 300 pounds sterling for hospital thrombolysis. Community thrombolysis led to an additional 0.09 years of life-expectancy gained compared with hospital thrombolysis at an additional cost of 61 pounds sterling per patient. Therefore, the incremental cost per life-year gained for the community thrombolysis service over the hospital thrombolysis service was 667 pounds sterling. Sensitivity analysis showed that estimates of cost per life-year gained were most sensitive to the estimates of survival.
This model suggests that, from the UK NHS perspective, implementing community thrombolysis may lead to extra survival but at extra cost over hospital thrombolysis. Although the incremental cost per life-year is modest, judgements still have to be made, however, as to whether the extra benefits estimated are worth the additional resources required. This requires consideration of the local context in which the service may be introduced.
有证据表明,患者越早到达医院并接受溶栓治疗,预后越好。GREAT(格兰扁地区早期阿尼普酶试验)通过一项随机对照试验,直接探讨了早期溶栓的问题,该试验评估了社区溶栓与医院溶栓的疗效。
本文旨在从英国国家医疗服务体系(NHS)的角度,利用GREAT的疗效数据,对社区溶栓与医院溶栓的成本和效益进行建模。
采用决策分析方法对这两种方案进行建模。对单个三级中心的资源使用和成本进行了估算。使用预期寿命的指数衰减近似法,从GREAT招募患者的4年随访中获得生命年有效性估计值。成本以2000/1年英镑价值计算。
社区溶栓的平均预期寿命为12.48年,医院溶栓的平均预期寿命为12.39年。社区溶栓成本为361英镑,医院溶栓成本为300英镑。与医院溶栓相比,社区溶栓导致预期寿命增加0.09年,每位患者额外成本为61英镑。因此,社区溶栓服务相对于医院溶栓服务每获得一个生命年的增量成本为667英镑。敏感性分析表明,每获得一个生命年的成本估计对生存估计最为敏感。
该模型表明,从英国国家医疗服务体系的角度来看,实施社区溶栓可能会带来额外的生存,但相对于医院溶栓会产生额外成本。尽管每生命年的增量成本适中,但仍需就是否值得投入额外资源来获得估计的额外效益做出判断。这需要考虑引入该服务的当地情况。